Belite Bio receives orphan drug status in Switzerland for retinal therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. NVDA
8. PRIM
9. PFE
10. TSLA

Go back to Belite Bio receives orphan drug status in Switzerland for retinal therapy
(NASDAQ: BLTE) Delayed: 146.39 -0.68 (0.46%)
Previous Close $147.07    52 Week High $ 
Open $145.94    52 Week Low $ 
Day High $148.65    P/E N/A 
Day Low $144.64    EPS $ 
Volume 72,491